Systematic review of cost and cost-effectiveness of different TB-screening strategies

BMC Health Services Research

Volumn 11, Issue , 2011, Pages

  Nienhaus, Albert ^a   Schablon, Anja ^a   Costa, José ^b   Diel, Roland ^c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b HOSPITAL DE SÃO JOÃO   (Portugal)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPARATIVE STUDY; CONTACT EXAMINATION; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; GERMANY; HEALTH CARE COST; HUMAN; INTERFERON GAMMA RELEASE ASSAY; LUNG TUBERCULOSIS; MALE; MASS SCREENING; METHODOLOGY; REVIEW; TUBERCULIN TEST;

CONTACT TRACING; COST-BENEFIT ANALYSIS; FEMALE; GERMANY; HEALTH CARE COSTS; HUMANS; INTERFERON-GAMMA RELEASE TESTS; MALE; MASS SCREENING; TUBERCULIN TEST; TUBERCULOSIS, PULMONARY;

EID: 80053374152     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-11-247     Document Type: Review

References (30)

1. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. Jensen PA, Lambert LA, Lademarco MF, Ridzon R, MMWR Recomm Rep 2005 54 1 141 16382216
2. What does tuberculin reactivity after bacille Calmette-Guerin vaccination tell us? Menzies D, Clin Infect Dis 2000 31 Suppl 3 71 S74
3. Specific immune-based diagnosis of tuberculosis. Andersen P, Munk ME, Pollock JM, Doherty TM, Lancet 2000 356 1099 1104 10.1016/S0140-6736(00)02742-2 11009160
4. Advances in the diagnosis and treatment of tuberculosis. Nahid P, Pai M, Hopewell PC, Proc Am Thorac Soc 2006 3 103 110 10.1513/pats.200511-119JH 16493157
5. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Pai M, Riley LW, Colford JM Jr, Lancet Infect Dis 2004 4 761 776 10.1016/S1473-3099(04)01206-X 15567126 (Pubitemid 39574348)
6. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Menzies D, Pai M, Comstock G, Ann Intern Med 2007 146 340 354 17339619 (Pubitemid 351650594)
7. Evidence based comparison of commercial interferon-gamma release assays for detecting active tuberculosis-a meta-analysis. Diel R, Loddenkemper R, Nienhaus A, Chest 2010 137 952 968 10.1378/chest.09-2350 20022968
8. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A, Am J Respir Crit Care Med 2008 177 1164 1170 10.1164/rccm.200711-1613OC 18276940 (Pubitemid 351717577)
9. Negative and Positive Predictive Value of a Whole-Blood IGRA for Developing Active TB-An Update. Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A, Am J Respir Crit Care Med 2010
10. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. Mazurek GH, Jereb J, Lobue P, Lademarco MF, Metchock B, Vernon A, MMWR Recomm Rep 2005 54 49 55 16357824
11. Clinical Guidelines 33. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. National Institute for Health and Clinical Excellence, London, UK 2007
12. Recommendations for environmental contact tracing in tuberculosis. German Central Committee against Tuberculosis. Diel R, Forbohm M, Loytved G, Haas W, Hauer B, Maffei D, et al. Gesundheitswesen 2007 69 488 503 10.1055/s-2007-980089 17926267 (Pubitemid 350004828)
13. Erkennung der Tuberkuloseinfektionen mittels Bluttest (Interfern-gamma). Schweiz Lungenliga, BAG Bulletin 2005 45 822 823
14. Cost-effectiveness analysis of QuantiFERON-TB 2nd generation used for detection of tuberculosis infection in contact investigations. Mori T, Harada N, Kekkaku 2005 80 675 686 16363672 (Pubitemid 41769552)
15. Direct costs of three models for the screening of latent tuberculosis infection. Wrighton-Smith P, Zellweger JP, Eur Respir J 2006 28 45 50 10.1183/09031936.06.00005906 16611659 (Pubitemid 44914259)
16. The QuantiFERON-TB-GOLD assay for tuberculosis screening in healthcare workers: a cost-comparison analysis. Fox BD, Kramer MR, Mor Z, Preiss R, Rusanov V, Fuks L, et al. Lung 2009 187 413 419 10.1007/s00408-009-9182-2 19830489
17. Cost optimisation of screening for latent tuberculosis in close contacts. Diel R, Nienhaus A, Lange C, Schaberg T, Eur Respir J 2006 28 35 44 10.1183/09031936.06.00011806 16571615 (Pubitemid 44914258)
18. Cost-effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the QuantiFERON-TB Gold IGRA alone is more cost-effective for immigrants from high burden countries. Hardy AB, Varma R, Collyns T, Moffitt SJ, Mullarkey C, Watson JP, Thorax 2010 65 178 180 10.1136/thx.2009.119677 19996345
19. Enhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention in Germany. Diel R, Schaberg T, Loddenkemper R, Welte T, Nienhaus A, Respir Med 2009 103 1838 53 10.1016/j.rmed.2009.07.008 19682884
20. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Graf von der Schulenburg JM, Greiner W, Jost F, Klusen N, Kubin M, Leidl R, et al. Value Health 2008 11 539 544 10.1111/j.1524-4733.2007.00301.x 18194408 (Pubitemid 352032814)
21. Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. Pooran A, Booth H, Miller RF, Scott G, Badri M, Huggett JF, et al. BMC Pulm Med 2010 10 7 10.1186/1471-2466-10-7 20170555
22. Cost-effectiveness of a new interferon-based blood assay, QuantiFERON(R)-TB Gold, in screening tuberculosis contacts. Marra F, Marra CA, Sadatsafavi M, Moran-Mendoza O, Cook V, Elwood RK, et al. Int J Tuberc Lung Dis 2008 12 1414 1424 19017451
23. Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. Oxlade O, Schwartzman K, Menzies D, Int J Tuberc Lung Dis 2007 11 16 26 17217125 (Pubitemid 46101841)
24. Cost Effectiveness of Interferon-gamma Release Assay for Tuberculosis Contact Screening in Japan. Kowada A, Takahashi O, Shimbo T, Ohde S, Tokuda Y, Fukui T, Mol Diagn Ther 2008 12 235 251 18652520
25. Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. de Perio MA, Tsevat J, Roselle GA, Kralovic SM, Eckman MH, Arch Intern Med 2009 169 179 187 10.1001/archinternmed.2008.524 19171815
26. Cost-effectiveness of QuantiFERON-TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection. Deuffic-Burban S, Atsou K, Viget N, Melliez H, Bouvet E, Yazdanpanah Y, Int J Tuberc Lung Dis 2010 14 471 481 20202306
27. Cost-effectiveness of Interferon-{gamma} Release Assay Screening for Latent Tuberculosis Infection Treatment in Germany. Diel R, Nienhaus A, Loddenkemper R, Chest 2007 131 1424 1434 10.1378/chest.06-2728 17494792 (Pubitemid 46762348)
28. Cost-effectiveness of interferon-gamma release assay testing for the treatment of latent tuberculosis. Diel R, Wrighton-Smith P, Zellweger JP, Eur Respir J 2007 30 321 332 10.1183/09031936.00145906 17504793 (Pubitemid 47194185)
29. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Diel R, Loddenkemper R, Nienhaus A, Chest 2010 137 952 968 10.1378/chest.09-2350 20022968
30. Interferon-{gamma} release assays for the diagnosis of latent M. tuberculosis infection: A systematic review and meta-analysis. Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, Kampmann B, et al. Eur Respir J 2010